Detailled Information

Name of the Instrument/Tool Visual Analogue Scale of the Fibromyalgia Impact Questionnaire (VASFIQ)
First Description

Boomershine CS, Emir B, Wang Y, Zlateva G. Simplifying Fibromyalgia Assessment: The VASFIQ Brief Symptom Scale. Ther Adv Musculoskelet Dis. 2011;3(5):215-26. Epub 2012/08/08.

Year 2011
Domains
Concept of constructs Global assessment
Population/Disease Disease specific
Originally developed for Fibromyalgia (FM)
Other rheumatic diseases
where can be applied (only if validated)
---
Additional population with no rheumatic diseases No
Language: Originally published in English
Available in Language Spanish
REFERENCE IDENTIFICATION
Author/s Boomershine CS, Emir B, Wang Y, Zlateva G
Title Simplifying Fibromyalgia Assessment: The VASFIQ Brief Symptom Scale
Journal Ther Adv Musculoskelet Dis
Year 2011
Vol 3
Num 5
Pages 215-26
Country United States
Language English
Other references of interest
No other References.
Instrument/Tool Translations References
No other References.
DEVELOPER CONTACT INFORMATION
Correspondence to Chad S. Boomershine
E-Mail chad.boomershine@vanderbilt.edu
Address Department of Medicine, Vanderbilt University, T3219 MCN, 1161 21st Avenue South, Nashville, TN 37232, USA
Website ---
Available ---
Links ---
DESCRIPTION OF THE INSTRUMENT
Type Of Measure Composite Index
Brief Description

A VAS + FIQ that quantify symptom severity of FM patient, designed for clinical use. It provides a mechanism for patients to effectively articulate their symptom burden to make diagnostic and treatment decision more accurate.

Number of Items 7
Range 0-70
Responses options/scale No
Developed for Clinical practice
PRACTICAL APPLICATION
Method of administration Self-administered
Recommendations to score ---
Score Interpretation ---
Cut-off points uses the full length questionnaire as reference
Cut-off points applied to ---
Smallest detectable change if described ---
Smallest detectable change applied to Not specified
Completion time by the patient 5 minutes
Scoring time by the assessor 0 minutes
Training to score initial training is required to ensure accurate self-completion of questionnaire.
Strengths ---
Limitations ---
OTHER COMMENTS
Other Comments

VASFIQ should not be used in isolation to make treatment decisions. But it is a rapid screen that can quantify symptom severity, but it is not intended for use as a diagnostic instrument.

 

A careful clinical evaluation is required to identify the underlying cause of symptoms and determine the most appropriate course of therapy.

It also can improve FM management by providing a mechanism for patients to effectively articulate their symptom burden and enhance the ability of clinicians to interpret the patient's complaints into a coherent intellectual framework from which to make diagnostic and treatment decisions.